ArticlePerioperative medicine (London, England)2026
Efficacy of postoperative tranexamic acid administration in patients undergoing proximal femoral tumor endoprosthesis reconstruction.
Article in Perioperative medicine (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePatients undergoing wide surgical resection and endoprosthesis of the proximal femur experience complications such as wound complications due to postoperative bleeding, complications related to blood replacement, infections related to surgical drains, and mobilization problems, increasing hospital length of stay and costs. Our aim is to evaluate the reduction in these problems in patients with postoperative tranexamic acid use.
methodsAll patients received a bolus of intravenous tranexamic acid at a dose of 15 cc/kg preoperatively, and local tranexamic acid was used during closure. This was applied to Group 1, while Group 2 received additional intravenous tranexamic acid at a dose of 1 g/day for 3 days postoperatively. Patients' risk of postoperative thromboembolic events, blood transfusion rates, postoperative wound healing problems, infection rates, mobilization times, physiotherapy initiation and hospital stay, and surgical drain removal times were compared retrospectively.
resultsPatients belonging to Group 2 (who received postoperative tranexamic acid) had earlier mobilization, initiation of physiotherapy, and shorter hospital stay (P < 0.001). They also had shorter surgical drain removal times and less blood transfusion volume (P < 0.001 for both). There were no significant differences in hematoma-related infection, age, gender, and primary/metastasis rates between the groups.
conclusionWe believe that postoperative tranexamic acid use will reduce complications related to blood replacement, reduce hospital-acquired infections and costs through earlier surgical drain removal and shorter hospital stays, and provide better protection against thromboembolic events and allow the patient to regain vital functions more quickly through earlier mobilization and initiation of physiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.